AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes inflammation of the large arteries.

Rinvoq is a Key Top-Line Driver for AbbVie Rinvoq is a key top-line driver for AbbVie. The drug generated sales of almost $6 billion in 2024, which was up 50.4% year over year, owing to continuous ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

近年来，生物制药行业的创新热潮持续涌动，尤其在自身免疫疾病的治疗上，企业纷纷加大研发投入。最近，艾伯维（AbbVie）旗下的药物RINVOQ获得了欧盟委员会的批准，用于治疗成人巨细胞动脉炎（Giant Cell Arteritis，GCA）。这一批准不仅标志着艾伯维在免疫疗法 ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...